Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)
Launched by ASTRAZENECA · Sep 12, 2005
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Main Inclusion Criteria:
- • Written informed consent
- • History of bronchial asthma for at least 6 months
- • Pre-treatment with CFC-beclomethasone dipropionate (CFC-BDP) ≥ 1000 mcg/day or equivalent and a long-acting beta agonist (LABA) either in free or fixed combination
- • FEV1 ≥ 80% of predicted
- Main Exclusion Criteria:
- • Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids or contraindications for the use of LABAs
- • COPD
- • Smoking with ≥10 pack-years
- • Pregnancy
- • Intention to become pregnant during the course of the study
- • Breast feeding
- • Lack of safe contraception
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lugano, , Switzerland
Bruxelles, , Belgium
Halen, , Belgium
Jette, , Belgium
Maison Saint Gérard, , Belgium
Namur, , Belgium
Oostende, , Belgium
Turnhout, , Belgium
Veurne, , Belgium
Aix En Provence, , France
Beziers, , France
Chauny Cedex, , France
Grasse, , France
La Rochelle, , France
Marseille, , France
Martigues Cedex, , France
Metz, , France
Montfermeil, , France
Montpellier Cedex, , France
Nice, , France
Nimes, , France
Paris, , France
Perpignan Cedex, , France
Vieux Conde, , France
Ancona, , Italy
Brescia, , Italy
Chieti, , Italy
Firenze, , Italy
Livorno, , Italy
Milano, , Italy
Milazzo (Me), , Italy
Napoli, , Italy
Pavia, , Italy
Pirri Cagliari, , Italy
Pordenone, , Italy
Roma, , Italy
Verona, , Italy
Almere, , Netherlands
Haarlem, , Netherlands
Harderwijk, , Netherlands
Heerlen, , Netherlands
Helmond, , Netherlands
Schiedam, , Netherlands
Utrecht, , Netherlands
Veldhoven, , Netherlands
Almeria, , Spain
Barcelona, , Spain
Córdoba, , Spain
Elche, , Spain
Guadalajara, , Spain
Madrid, , Spain
Requena, , Spain
San Sebastián, , Spain
Valencia, , Spain
Basel, , Switzerland
Bellinzona, , Switzerland
Bern, , Switzerland
Bruderholz, , Switzerland
La Chauxe De Fonds, , Switzerland
Münchenstein, , Switzerland
Münsingen, , Switzerland
Münsterlingen, , Switzerland
Zürich, , Switzerland
Belfast, Irland, , United Kingdom
Belfast, , United Kingdom
Bradford On Avon, Wiltshire, , United Kingdom
Chesterfield Derbyshire, , United Kingdom
Chippenham, Wiltshire, , United Kingdom
Co. Antrim, , United Kingdom
Downpatrick, Northern Ireland, , United Kingdom
Dronfield, , United Kingdom
Glengormley Newtownabbey, , United Kingdom
Glengormley, , United Kingdom
Hastings, , United Kingdom
Maidenhead, Berks, , United Kingdom
Nottingham, , United Kingdom
Solihull, , United Kingdom
Warminster Wiltshire, , United Kingdom
Watford, , United Kingdom
Patients applied
Trial Officials
AstraZeneca AstraZeneca
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials